Outcomes of liver transplantation in children with Langerhans cell histiocytosis : Experience from a quaternary care center
© 2022 Wiley Periodicals LLC..
BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare but important cause of end-stage liver disease in children. Conventional chemotherapeutic agents that are otherwise the standard-of-care in LCH may be counterproductive in patients with hepatic decompensation. Furthermore, the precise role of liver transplantation (LT) in the management of LCH remains unclear.
METHODS: Review of a prospectively collected database (January 2014 to December 2020) of children with liver disease was performed. All clinical details of patients with LCH managed at our center were collected and data analyzed. Based on the outcomes, a management algorithm was proposed.
RESULTS: Of the eight (five male) patients referred to our unit, six (75%) underwent LT (four and two for compensated and decompensated cirrhosis, respectively). Median age at diagnosis of LCH was 25 (range: 9-48) months. Two patients, who had previously completed LCH-specific chemotherapy, underwent upfront LT for compensated cirrhosis. Other two patients with compensated cirrhosis showed evidence of active disease. They underwent LT following completion of chemotherapy. Two children with decompensated cirrhosis also had evidence of active disease and were started on modified chemotherapy Both of them had progression of liver disease while on chemotherapy. Hence, an urgent LT was performed which was followed by completion of chemotherapy in these patients. On a median follow-up of 30.5 (10.5-50) months, all post-LT patients were alive with stable graft function and showed no disease recurrence.
CONCLUSION: We demonstrate that an algorithmic approach, along with newer chemotherapeutic agents, results in excellent outcomes in LCH patients with liver involvement. Larger multicentric studies on this rare disease are, however, needed to validate our findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Pediatric blood & cancer - 70(2023), 1 vom: 28. Jan., Seite e30024 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Menon, Jagadeesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Algorithmic approach |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 24.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/pbc.30024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348314795 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348314795 | ||
| 003 | DE-627 | ||
| 005 | 20231226035901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/pbc.30024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348314795 | ||
| 035 | |a (NLM)36317422 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Menon, Jagadeesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of liver transplantation in children with Langerhans cell histiocytosis |b Experience from a quaternary care center |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 24.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare but important cause of end-stage liver disease in children. Conventional chemotherapeutic agents that are otherwise the standard-of-care in LCH may be counterproductive in patients with hepatic decompensation. Furthermore, the precise role of liver transplantation (LT) in the management of LCH remains unclear | ||
| 520 | |a METHODS: Review of a prospectively collected database (January 2014 to December 2020) of children with liver disease was performed. All clinical details of patients with LCH managed at our center were collected and data analyzed. Based on the outcomes, a management algorithm was proposed | ||
| 520 | |a RESULTS: Of the eight (five male) patients referred to our unit, six (75%) underwent LT (four and two for compensated and decompensated cirrhosis, respectively). Median age at diagnosis of LCH was 25 (range: 9-48) months. Two patients, who had previously completed LCH-specific chemotherapy, underwent upfront LT for compensated cirrhosis. Other two patients with compensated cirrhosis showed evidence of active disease. They underwent LT following completion of chemotherapy. Two children with decompensated cirrhosis also had evidence of active disease and were started on modified chemotherapy Both of them had progression of liver disease while on chemotherapy. Hence, an urgent LT was performed which was followed by completion of chemotherapy in these patients. On a median follow-up of 30.5 (10.5-50) months, all post-LT patients were alive with stable graft function and showed no disease recurrence | ||
| 520 | |a CONCLUSION: We demonstrate that an algorithmic approach, along with newer chemotherapeutic agents, results in excellent outcomes in LCH patients with liver involvement. Larger multicentric studies on this rare disease are, however, needed to validate our findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Langerhans cell histiocytosis | |
| 650 | 4 | |a algorithmic approach | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a liver transplantation | |
| 650 | 4 | |a modified chemotherapy | |
| 700 | 1 | |a Shanmugam, Naresh |e verfasserin |4 aut | |
| 700 | 1 | |a Valamparampil, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Vij, Mukul |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vimal |e verfasserin |4 aut | |
| 700 | 1 | |a Munirathnam, Deenadayalan |e verfasserin |4 aut | |
| 700 | 1 | |a Hakeem, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Rammohan, Ashwin |e verfasserin |4 aut | |
| 700 | 1 | |a Rela, Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric blood & cancer |d 2004 |g 70(2023), 1 vom: 28. Jan., Seite e30024 |w (DE-627)NLM144579871 |x 1545-5017 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2023 |g number:1 |g day:28 |g month:01 |g pages:e30024 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/pbc.30024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2023 |e 1 |b 28 |c 01 |h e30024 | ||